Rarity Bioscience provides ultrasensitive multiplex assays for mutation detecting in blood and other liquid biopsies for research, pharma and clinics.
 
The sensitivity of our precision diagnostics technology enables patient stratification, treatment choice & monitoring, early MRD and relapse detection and post-transplantation follow-up for optimized cancer care. 
It also enables refined inclusion stratification and monitoring in clinical trials.

The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.

Biotechnology

Clinical Trials

Health Diagnostics

Life Sciences

Rarity Bioscience

Org chart

Teams

Similar companies